Physician’s Profile

Markus Siegelin, MD

Department of Pathology & Cell Biology
Division of Anatomic Pathology

MD, 2005 - Johann-Wolfgang-Goethe University, Frankfurt am Main Germany

2006-2007 Intern in Neurology - Ruprecht-Karls-University, Heidelberg, Germany.

2007 - 2009 Fellowship Neuropathology - Ruprecht-Karls-University, Heidelberg, Germany. Post-Doctoral

2009-2010 Research Fellowship - University of Massachusetts

Residency in Anatomic Pathology - New York Presbyterian Hospital, Columbia University Medical Center, College of Physicians and Surgeons


Board Certificates
Anatomic Pathology
Honors & Awards:

2007 Rudi-Busse Dissertation Award for the best doctoral thesis in 2007, Johann-Wolfgang-Goethe University, Frankfurt am Main, Germany

2007 Young Investigator Award, Ruprecht-Karls-University, Heidelberg, Germany

2009 Post-Doctoral Research Fellowship awarded by German Research Foundation.

2012 Stowell-Orbison Award, United States & Canadian Academy of Pathology, Vancouver, BC, Canada.

2013 American Association for Cancer Research (AACR) and National Brain Tumor Society Career Development Award for Translational Brain Tumor Research

2013 Translational Grant Program, American Brain Tumor Association (ABTA)

2014-2019 National Institue of Health, NINDS, K08 Career Development Award

2016-2021 National Institue of Health, NINDS, R01 Research Grant

2016 BCURED Fighting Brain Cancer Award


Karpel-Massler G, Ramani D, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. Oncotarget. 2016 Jun 7;7(23):33512-28. doi: 10.18632/oncotarget.9257.

Karpel-Massler G, Horst BA, Shu C, Chau L, Tsujiuchi T, Bruce JN, Canoll P, Greene LA, Angelastro JM, Karpel-Massler G, Horst BA, Shu C, Chau L, Tsujiuchi T, Bruce JN, Canoll P, Greene LA, Angelastro JM, Siegelin MD. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. Clin Cancer Res. 2016 Sep 15;22(18):4698-711. doi: 10.1158/1078-0432.CCR-15-2827.

Karpel-Massler G, Banu MA, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Oncotarget. 2016 Mar 15;7(11):12791-805. doi: 10.18632/oncotarget.7302.

Karpel-Massler G, Bâ M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget. 2015 Nov 3;6(34):36456-71. doi: 10.18632/oncotarget.5505.

Ghosh JC, Siegelin MD, Vaira V, Faversani A, Tavecchio M, Chae YC, Lisanti S, Rampini P, Giroda M, Caino MC, Seo JH, Kossenkov AV, Michalek RD, Schultz DC, Bosari S, Languino LR, Altieri DC. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J Natl Cancer Inst. 2015 Feb 3;107(3). pii: dju502. doi: 10.1093/jnci/dju502.

Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH, Siegelin MD. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res. 2014 Jul;12(7):987-1001. doi: 10.1158/1541-7786.MCR-13-0650.

Siegelin MD. Inhibition of the mitochondrial Hsp90 chaperone network: A novel, efficient treatment strategy for cancer? Cancer letters. (2013). Jun 10;333(2):133-46.

Siegelin, M.D. Utilization of the cellular stress response to sensitize cancer cells to TRAIL - mediated apoptosis. Expert Opin Ther Targets. (2012). 16(8): 801-17.

Siegelin, M. D., T. Dohi, C. M. Raskett, G. M. Orlowski, C. M. Powers, C. A. Gilbert, A. H. Ross, J. Plescia and D. C. Altieri. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. (2011). 121(4): 1349-60.

Ghosh, J. C., M. D. Siegelin, T. Dohi and D. C. Altieri. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res. (2010). 70(22): 8988-93.

Kang, B. H., M. D. Siegelin, J. Plescia, C. M. Raskett, D. S. Garlick, T. Dohi, J. B. Lian, G. S. Stein, L. R. Languino and D. C. Altieri. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res. (2010). 16(19): 4779-88.

Elias, A., M. D. Siegelin, A. Steinmuller, A. von Deimling, U. Lass, B. Korn and W. Mueller. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res. (2009). 15(17): 5457-65.